Day: September 21, 2020

1593-08-4, 2-Formylquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 22 (4S)-3-Fluoro-4-hydroxy-4-({4-[(2-quinoxalinylmethyl)amino]-l- piperidinyl}methyl)-4,5-dihydro-7Hr-pyrrolo[3,2,l-^]-l|>5-naplithyridin-7-one (Enantiomer El) dihydrochlorideA mixture of (4S)-4-[(4-amino-l-piperidinyl)methyl]-3-fluoro-4-hydroxy-4,5- dihydro-7H-pyrrolo[3,2,l-Je]-l,5-naphthyridin-7-one (El enantiomer) (80 mg, 0.25 mmol) and 2-quinoxalinecarbaldehyde (30mg, 0.20 mmol) in dichloromethane/methanol (0.5 mL/0.1 mL) was treated with sodium triacetoxyborohydride (127mg, 06 mL). After one hour, the reaction mixture was treated with a saturated aqueous solution of sodium bicarbonate (2 mL) and chloroform (1 mL). The mixture was shaken for 5 minutes. The aqueous layer was further extracted with dichloromethane/methanol (lmL/0.2mL). The combined organic extracts were added to the top of a column and and chromatographed eluting with a 0-30% gradient of methanol/dichloromethane affording the free base of the title compound as a clear oil (30 mg, 33%). deltaH (CDCl3, 250MHz)1.45-1.73 (2H, m), 1.90-2.10 (2H, m), 2.40 (IH, t), 2.55 (IH, t), 2.70 (IH, m), 2.90 (IH, d), 2.95-3.07 (2H, m), 3.27 (IH, d), 4.25 (2H, s), 4.35 (IH, d), 4.45 (IH, d), 6.85 (IH, d), 7.25-7.32 (2H, m), 7.88 (IH, d), 8.05-8.15 (2H, m), 8.38 (IH, s), 8.90 (IH, s). MS (+ve ion electrospray) m/z 461 (MH+).

1593-08-4, The synthetic route of 1593-08-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GLAXO GROUP LIMITED; WO2007/71936; (2007); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

50998-17-9, Known quinoxaline xvi (CAS 50998-17-9, 1.0 g, 4.78 mmol) is dissolved in acetonitrile (20 mL) under inert atmosphere. Triethylamine (6.6 mL, 47.8 mmol) is added, followed by known pyrazole xvii (CAS 1354706-26-5, 850 mg, 5.26 mmol) and palladium tetrakis (665 mg, 0.478 mmol). The reaction is heated to 70 C and stirred for 18 horns. The solvent is removed by distillation under vacuum at 55 C, and the resultant product is purified by flash chromatography (30% ethyl acetate in petroleum ether) to give xviii in 80% yield.

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; CLAVIUS PHARMACEUTICALS, LLC; SAWYER, J., Scott; (109 pag.)WO2019/5241; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13708-12-8,5-Methylquinoxaline,as a common compound, the synthetic route is as follows.

General procedure: N-heteroarene (1 mmoL, 80 mg), alpha-keto acid (3 mmol), Formic acid (1 mmol, 38 muL), ammonium persulfate (3 mmoL, 685 mg), ferrous sulfate heptahydrate (0.08 mmoL, 22 mg) and 20 mL of mixed solvent (DCM: H2O = 3: 1) , 0.1 mL DMSO was added into a 25 mL round-bottomed flask. The mixture was stirred at 40 oC until TLC analysis indicating that the reaction was complete (witnessed by the disappearance of the N-heteroarene). After separation of organic phase, the residue was neutralized by 0.1 M sodium hydroxide solution, then extracted with DCM (3¡Á20 mL), combined the organic phases, dried over Na2SO4, and concentrated in vacuo. The residue was N-heteroarene (1 mmoL, 80 mg), alpha-keto acid (3 mmol), Formic acid (1 mmol, 38 muL), ammonium persulfate (3 mmoL, 685 mg), ferrous sulfate heptahydrate (0.08 mmoL, 22 mg) and 20 mL of mixed solvent (DCM: H2O = 3: 1) , 0.1 mL DMSO was added into a 25 mL round-bottomed flask. The mixture was stirred at 40 oC until TLC analysis indicating that the reaction was complete (witnessed by the disappearance of the N-heteroarene). After separation of organic phase, the residue was neutralized by 0.1 M sodium hydroxide solution, then extracted with DCM (3¡Á20 mL), combined the organic phases, dried over Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography on silica gel using a mixture of petroleum ether/EtOAc (v : v = 20 : 1) as eluent to afford the desired pure product.

13708-12-8, The synthetic route of 13708-12-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Wang, Xiu-Zhi; Zeng, Cheng-Chu; Tetrahedron; vol. 75; 10; (2019); p. 1425 – 1430;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.89891-65-6,7-Bromo-2-chloroquinoxaline,as a common compound, the synthetic route is as follows.

89891-65-6, a) 7-bromoquinoxaline-2-amine 7-bromo-2-chloroquinoxaline (1.0 g, 4.13 mmol) and ammonia (7 mL) were added to 1,4-dioxane (7 mL). After reaction under agitation at 70 C for 5 h, the reaction mixture was cooled to rt. Water (10 mL) was added, and EA (30 mL*2) was used for extraction. The organic phases were combined, washed with a saturated saline solution (50 mL), dried with anhydrous sodium sulfate, filtered, and concentrated at reduced pressure to obtain a crude compound. Isolation and purification by column chromatography (silica gel, PE: EA = 3:1 as an eluant) were performed to obtain the targeted compound (500 mg, 54.2% yield, yellow solid). LC-MS (ESI): m/z (M+1) 223.99.

As the paragraph descriping shows that 89891-65-6 is playing an increasingly important role.

Reference£º
Patent; Impact Therapeutics, Inc; CAI, Suixiong; TIAN, Ye Edward; (74 pag.)EP3567041; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

6639-87-8,6639-87-8, 6-Nitroquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

b. Quinoxalin-6-amine To a solution of 6-nitroquinoxaline (17.0 g, 0.097 mol) in MeOH (500 mL) was added hydrazine hydrate (19.4 g, 0.39 mol) and Raney Ni (2.0 g). The mixture was stirred at room temperature for 1 h. The mixture was then filtered, and the filtrate was concentrated under reduce pressure to give quinoxalin-6-amine as a yellow solid (14.0 g, yield 99%). ESI MS: m/z 146.1 [M+H]+.

6639-87-8 6-Nitroquinoxaline 96029, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; Sunovion Pharmaceuticals Inc.; US2012/178748; (2012); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

50998-17-9, 6-Bromo quinoxaline (2.0 g, 9.5 mmcl) in toluene (20 mL) was degassed for 30 mm. To thissolution, 1-ethoxy vinyl tributyltin (3.8 g, 10.5 mmol) and bis(triphenylphosphine)palladium dichloride (0.67 g, 0.95 mmol) were added at rt and stirred for 16 hours at 90 C. The reaction mixture was cooled to rt and filtered through celite. After evaporation of the solvent, 6 N HCI solution in water (20 mL) was added and the mixture was stirred for I hour at rt. It was concentrated and neutralized with sat. NaHCO3. The desired product wasextracted with DCM (100 mL), dried over Na2SO4 and concentrated. The crude productwas purified by column chromatography to afford the title compound (brown solid). 1H NMR(400 MHz, DMSO-d6): 6 9.06-9.04 (m, 2H), 8.70 (d, J=2.4 Hz, I H), 8.28 (t, J = 2.8 Hz, I H),8.16 (d, J = 11.6 Hz, IH), 2.97 (5, 3H). LCMS: (Method A) 173 (M+H), Rt. 2.25 mm,99.06% (Max).

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; ASCENEURON S. A.; QUATTROPANI, Anna; KULKARNI, Santosh, S.; GIRI, Awadut, Gajendra; (280 pag.)WO2017/144633; (2017); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

2379-56-8, 6-Nitroquinoxaline-2,3-dione is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

6-Nitroquinoxaline-2,3-(1H,4H)-dione (12 g, 59.0 mmol), thionylchloride (28.1 g, 236 mmol) and catalytic amount of dimethylformamide (0.86 g, 11.8 mmol) were dissolved in dichloroethane solvent, followed by reflux stirring for 2 hours. Upon completion of the reaction, the solvent was eliminated. The temperature was lowered to 05C. to solidify the product. The resulting solid was filtered, and dried under reduced pressure. As a result, 12.3 g of a target compound was obtained (87% yield). Mass (M+H +): 244.1 1H NMR (300 MHz, DMSO-d6): delta8.31 (d, J=9.15 Hz, 1H), 8.60 (d, J=9.15 Hz, 1H), 8.88 (s, 1H)., 2379-56-8

As the paragraph descriping shows that 2379-56-8 is playing an increasingly important role.

Reference£º
Patent; Dong Wha Pharm. Co., Ltd.; Korea Research Institute of Chemical Technology; Lee, Kwangho; Choi, Gildon; Ali, Imran; Lee, Joo Yun; Lee, Jin Soo; Park, Whui Jung; Kim, Yong Tae; Kim, Seung Hwan; Kim, Jung Hwan; Lim, Jae-Kyung; (250 pag.)US2020/39984; (2020); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.55687-02-0,6-Bromo-2-chloroquinoxaline,as a common compound, the synthetic route is as follows.

55687-02-0, Methyl (S)-3-methyl-1-oxo-1-((S)-2-(6-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxalin-2-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-1-yl)butan-2-ylcarbamate In a 10 mL seal tube, methyl (S)-3-methyl-1-oxo-1-((S)-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-1-yl)butan-2-ylcarbamate (100 mg, 213 mmol, Eq: 1.00), 6-bromo-2-chloroquinoxaline (51.8 mg, 213 mumol, Eq: 1.00) and cesium carbonate (139 mg, 425 mumol, Eq: 2.0) were combined with 1,4 dioxane (2.00 ml) and water (0.4 ml) to give a light brown solution. It was degassed for 10 min and tetrakis(triphenylphosphine)palladium (0) (24.6 mg, 21.3 mumol, Eq: 0.1) was added. The reaction mixture was heated to 80 C. and stirred for 16 h. It was diluted with EtOAc (6 ml), filtered through celite, concentrated in vacuo and purified on a silica gel column (CH2Cl2, 2%, 3%, 5%, 8%, 10% MeOH/CH2Cl2) to afford methyl (S)-1-((S)-2-(5-(6-bromoquinoxalin-2-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate as a solid (100 mg, 85.3%). ESI-LRMS m/e calcd for C26H27BrN6O3 [M+] 551, found 552 [M+H+].

The synthetic route of 55687-02-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Alam, Muzaffar; Berthel, Steven Joseph; Brinkman, John A.; Hawley, Ronald Charles; Li, Hongju; Palmer, Wylie Solang; Pietranico-Cole, Sherrie; Sarabu, Ramakanth; Smith, Mark; So, Sung-Sau; Yi, Lin; Zhai, Yansheng; Zhang, Qiang; Zhao, Shu-Hai; US2012/230951; (2012); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

6298-37-9,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.6298-37-9,Quinoxalin-6-amine,as a common compound, the synthetic route is as follows.

Synthesis of 4-((quinoxalin-6-ylamino)methyl)-1H-pyrazole-5-carboxylic acid (5-B) To a suspension of product (4-B) (100 mg, 0.71 mmol) and quinoxalin-6-amine (104 mg, 0.71 mmol) in a solution of 1,2-dichloroethane (DCE, 5 mL) and DMF (5 mL) was added acetic acid (5 drops) at rt. The reaction mixture was then stuffed for 16 h. MeOH (5 mL) was added, followed by NaBH4 (100 mg, 2.63 mmol). The reaction mixture was stuffed at rt for another 30 mm.The solution was diluted with ethyl acetate (30 mL); washed with 5 % citric acid (10 mL) and brine (20 mL); dried over Na2504 and concentrated to give crude product (5-B) (200 mg, 99 %) as a yellow solid. LC-MS (M+H) = 270.

The synthetic route of 6298-37-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; X-RX, INC.; KEEFE, Anthony, D.; WAGNER, Richard, W.; CLARK, Matthew; ZHANG, Ying; GIKUNJU, Diana; CUOZZO, John; THOMSON, Heather; WO2013/106414; (2013); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.49679-45-0,Ethyl 3-chloroquinoxaline-2-carboxylate,as a common compound, the synthetic route is as follows.,49679-45-0

General procedure: Method A: a solution of compound 3 (1.11 g, 4.70 mmol), 3- aminophenol (622 mg, 5.70 mmol) and p-TSA, as a catalyst, in absolute ethanol (40 mL) was refluxed for 110 h. Ethanol was then evaporated under reduced pressure, and the resulting residue was purified by silica column chromatography using cyclohexane with ethyl acetate gradient (0e50%) as eluent to give the desired compound 4a (1.0 g, 69%) as a red powder.

As the paragraph descriping shows that 49679-45-0 is playing an increasingly important role.

Reference£º
Article; Oyallon, Bruno; Brachet-Botineau, Marie; Loge, Cedric; Bonnet, Pascal; Souab, Mohamed; Robert, Thomas; Ruchaud, Sandrine; Bach, Stephane; Berthelot, Pascal; Gouilleux, Fabrice; Viaud-Massuard, Marie-Claude; Denevault-Sabourin, Caroline; European Journal of Medicinal Chemistry; vol. 154; (2018); p. 101 – 109;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider